• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/24/21 10:19:11 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PULM alert in real time by email
    SC 13G 1 tm217745d8_sc13g.htm SC 13G

     

     

     

    CUSIP No: 74584P202

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. ____)*

     

    Pulmatrix, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    74584P202

    (CUSIP Number)

     

    February 11, 2021

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No: 74584P202

     

    (1) NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands

    NUMBER OF  (5) SOLE VOTING POWER
          
    SHARES  0
          
    BENEFICIALLY  (6) SHARED VOTING POWER **
          
    OWNED BY  3,500,000
          
          
    EACH  (7) SOLE DISPOSITIVE POWER
          
    REPORTING  0
          
    PERSON WITH   (8) SHARED DISPOSITIVE POWER **
          
       3,500,000

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      3,500,000
       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
     
      6.2%  
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No: 74584P202

     

    (1) NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
       
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
       
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware

    NUMBER OF   (5) SOLE VOTING POWER
     
    SHARES   0
     
    BENEFICIALLY   (6) SHARED VOTING POWER **
     
    OWNED BY   3,500,000
         

    EACH   (7) SOLE DISPOSITIVE POWER
     
    REPORTING   0
         
     
    PERSON WITH   (8) SHARED DISPOSITIVE POWER **
     
        3,500,000

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      3,500,000
         
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
       
       
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
     
      6.2%
         
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No: 74584P202

     

    Item 1.

     

    (a)Name of Issuer

     

    Pulmatrix, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    99 Hayden Avenue, Suite 390, Lexington, MA 02421

     

    Item 2(a).Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e)CUSIP Number

     

    74584P202

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

     

     

    CUSIP No: 74584P202

     

    (b)¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The Company’s Prospectus Supplement (to Prospectus dated March 15, 2019, Registration No. 333-230225), filed on February 16, 2021, indicates there were 56,105,097 Shares outstanding as of the completion of the offering of the Shares referred to therein.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

     

     

    CUSIP No: 74584P202

     

    Item 7.         Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No: 74584P202

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief,each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 24, 2021

     

    CVI INVESTMENTS, INC. HEIGHTS CAPITAL MANAGEMENT, INC.
       
    By: Heights Capital Management, Inc. pursuant to a By: /s/ Brian Sopinsky
    Limited Power of Attorney, a copy of which is attached Name:  

    Brian Sopinsky

     as Exhibit I hereto Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name:   Brian Sopinsky  
    Title: Secretary  

     

     

     

    CUSIP No: 74584P202

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney
    II   Joint Filing Agreement

     

     

     

    CUSIP No: 74584P202

     

    Exhibit I

     

    LIMITED POWER OF ATTORNEY

     

    THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. (hereinafter called "the Company"), whose Registered Office is situated at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.

     

    WHEREAS, by agreement dated July 16, 2015, by and between the Company and Heights Capital Management, Inc., the Company expressly authorized Heights Capital Management, Inc. to enter into transactions in certain designated areas as defined in the Discretionary Investment Management Agreement attached hereto marked "Appendix l."

     

    NOW THIS DEED WITNESSETH that William Walmsley, Director of the Company, hereby appoints on behalf of the Company the firm of HEIGHTS CAPITAL MANAGEMENT, INC., which through its officers, directors and employees is hereby formally granted limited power of attorney for the purpose of entering into transactions on behalf and for the account of the Company; and to take all actions on behalf of the Company as may be necessary to consummate such transactions, including but not limited to making, negotiating; signing, endorsing, executing, acknowledging and delivering in the name of the Company all applications, contracts, agreements, notes, statements, certificates, proxies and any other instruments of whatever kind and nature as may be necessary or proper in connection with the entering into of such transactions, instructing the transfer of funds where necessary with respect to such transactions, and performing all of the services specified under the Discretionary Investment Management Agreement with respect to such transactions.

     

    IN WITNESS WHEREOF, the Company has caused this Limited Power of Attorney to take effect on the day and year above written.

     

     

      CVI Investments, Inc.

     

      By: /s/ William Walmsley
        William Walmsley, Director

     

     

     

    CUSIP No: 74584P202

    EXHIBIT II

     

    JOINT FILING AGREEMENT

     

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of common stock of Pulmatrix, Inc., $0.0001 par value per share, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

     

    Dated as of February 24, 2021

     

    CVI INVESTMENTS, INC.

    HEIGHTS CAPITAL MANAGEMENT, INC.

       
    By: Heights Capital Management, Inc. By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney Name: Brian Sopinsky
      Title: Secretary
    By: /s/ Brian Sopinsky

    Name:

    Brian Sopinsky

     
     Title: Secretary  

     

     

    Get the next $PULM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PULM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PULM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Batycky Richard P.

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:40 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Varadan Anand

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:42 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Cabell Christopher

      4 - Pulmatrix, Inc. (0001574235) (Issuer)

      1/30/23 4:05:43 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    SEC Filings

    See more
    • SEC Form 424B3 filed by Pulmatrix Inc.

      424B3 - Pulmatrix, Inc. (0001574235) (Filer)

      5/9/25 4:55:25 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-4/A filed by Pulmatrix Inc.

      S-4/A - Pulmatrix, Inc. (0001574235) (Filer)

      5/6/25 9:51:14 PM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-4/A filed by Pulmatrix Inc.

      S-4/A - Pulmatrix, Inc. (0001574235) (Filer)

      4/17/25 8:39:23 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

      Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass., March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financi

      3/21/25 8:05:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

      SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. ("Cullgen"), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK protein degrader for the treatment of pain. CG001419 is a highly active small molecule designed to selectively degrade both mutant and wild-type TRK proteins and is being developed to be a new, non-opioid, non-NSAID analgesic therapy as part of a new class of pain signal inhibitors that have the

      1/22/25 8:00:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pulmatrix and Cullgen Announce Proposed Merger

      Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and one for the treatment of acute and chronic pain Combined company expected to have approximately $65 million of cash and cash equivalents at close to provide funding through multiple clinical milestones and expected runway through 2026 As part of merger agreement, Pulmatrix intends to divest its assets including its acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology Cullgen and Pulmatrix will host an informational webcast about the propose

      11/13/24 9:00:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Financials

    Live finance-specific insights

    See more
    • Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

      PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 providing cash runway into Q2 2024 LEXINGTON, Mass., March 30, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2022 and provided a corporate update on its development programs.

      3/30/23 9:05:00 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Pulmatrix with a new price target

      HC Wainwright & Co. reiterated coverage of Pulmatrix with a rating of Buy and set a new price target of $5.00 from $10.00 previously

      4/13/21 6:23:02 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      1/2/24 9:42:57 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      2/8/23 6:08:04 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

      SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

      1/10/23 11:21:19 AM ET
      $PULM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PULM
    Leadership Updates

    Live Leadership Updates

    See more
    • Pulmatrix appoints Director Anand Varadan

      LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to

      7/27/21 10:00:00 AM ET
      $PULM
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals